ArticleMedicine2026
Palivizumab prophylaxis and risk of RSV infection among moderate-to-late preterm infants: A nationwide Korean cohort study from 2018 to 2022.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants, and preterm infants are at higher risk of severe illness. While RSV immunoprophylaxis is widely considered necessary for very preterm infants in most countries, its efficacy in moderate-to-late preterm infants (MLPI) remains controversial. This study aimed to evaluate the preventive and therapeutic effects of palivizumab in MLPI, using data from the National Health Insurance Service of Korea. We analyzed the National Health Insurance Service data for infants born during the RSV season (October-March) from 2018 to 2022. Infants with a gestational age of 32 weeks 0 days' to 36 weeks 6 days' gestation were categorized as MLPI and those born between 37 weeks 0 days' and 41 weeks 6 days' gestation as full-term infants. Infants with congenital anomalies or severe cardiac diseases were excluded. Both groups were divided according to palivizumab administration. We compared the RSV infection rates and hospitalization duration. Of the 593,419 infants, 137,452 were excluded. Among 440,163 full-term infants, 938 (0.23%) received palivizumab, compared with 2096 (13.26%) of 15,804 MLPI. In full-term infants, RSV infection occurred in 0.68% of the non-recipients and 0.21% of the recipients. Among the MLPI, the infection rates were 1.18% in non-recipients and 0.62% in recipients, indicating a statistically significant reduction. Logistic regression analysis revealed that palivizumab reduced the risk of RSV infection in MLPI by an approximately 53% lower odds (adjusted odds ratio, 0.47; P = .011). Palivizumab significantly reduced the incidence and severity of RSV infection in MLPI in Korea. This study provides crucial nationwide baseline data on the RSV disease burden in this vulnerable population immediately before the introduction of novel prophylactic strategies such as nirsevimab, and can serve as evidence for future health policy decisions and cost-effectiveness analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.